Enter assignee name

Trademarks = 2

Forward Citations = 0

Loading Chart...

13 inventors (with patents filed for the assignee):

Tetsuya Yamagata (5 out of 5 patents)

Yuanbo Qin (5 out of 5 patents)

Iain Robert Thompson (5 out of 5 patents)

4. Osamu Nureki (2 out of 13 patents)

5. Hiroshi Nishimasu (2 out of 12 patents)

6. Haruhiko Morita (2 out of 3 patents)

7. Hisato Hirano (2 out of 4 patents)

8. Shohei Kajimoto (2 out of 2 patents)

9. Keith M Connolly (2 out of 2 patents)

10. Eiji Yoshimi (1 out of 3 patents)

11. Katsuro Yoshioka (1 out of 2 patents)

12. Nidhi Khanna (1 out of 1 patent)

13. Talha Akbulut (1 out of 1 patent)

5 patents: Sort by Forward Citations

1. 12152259 - Modified CAS9 protein, and use thereof (2024-11-26),

2. 11591621 - Method of treating diseases associated with elevated KRAS expression using CRISPR-GNDM system (2023-02-28),

3. 11530396 - Modified CAS9 protein, and use thereof (2022-12-20),

4. 11473071 - Method for treating muscular dystrophy by targeting utrophin gene (2022-10-18),

5. 11439692 - Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system (2022-09-13),

Modalis Therapeutics Corporation is a biopharmaceutical company dedicated to developing novel therapies for neurological disorders. With a focus on neurodegenerative diseases such as Alzheimer's and Parkinson's, Modalis is committed to advancing innovative treatments that improve the quality of life for patients. Through cutting-edge research and strategic partnerships, Modalis is on a mission to address unmet medical needs and make a meaningful impact on the field of neuroscience.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 13 2026

5 Patents

#10 in Chuo-ku

#6,495 in Japan

Chuo-ku, Japan

Modalis Therapeutics Corporation